Skip to content

Comparable study in magnetic seizure therapy and electroconvulsive therapy for depressive episode

Comparable study in magnetic seizure therapy and electroconvulsive therapy for depressive episode

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-17010740
Enrollment
Unknown
Registered
2017-02-27
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive episode

Interventions

MST group:MST

Sponsors

Beijing An Ding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Agde 18-50 years; 2. Have a DSM-?diagnosis of depressivee episode; 3. Hamilton Depression Rating Scale 17(HAMD-17)score=18; 4. Patients who are recommended the convulsive therapy; 5. All subjects and their guardians are informed of the details and matters needing attention of the study before attending the study. And all subjects are voluntarily participating, subjects and their guardians sign informed consent in writing at the same time before the study.

Exclusion criteria

Exclusion criteria: 1. Patients with organic encephalopathy and dementia, serious physical disease, substance abuse, head trauma, dianxianshi, Parkinson's and other neurological diseases, ventricular arrhythmias and other unsuitable patients; 2. Patients whi are unwilling to co-operate; 3. Patients who are planned pregnancy or on pregnancy; 4. Patients who are allergic to propofol or etomidate and muscle relaxant; 5. Patients who accept ECT or repetitive transcranial magnetic stimulation(rTMS) within one month; 6. Patients who take a long-acting Anticonvulsant drug in 3 days before the group; 7. Patients who have other diseases that affect convulsive therapy; 8. Patients with treatment-refractory depression; 9. Patients with metal products such as pacemaker, deep brain stimulator, vagus stimulator in the body.

Design outcomes

Primary

MeasureTime frame
efficacy;

Countries

China

Contacts

Public ContactXin Ma

Beijing An Ding Hospital, Capital Medical University

maxinanding@vip.163.com+86 13701364608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026